FBXW5 acts as a negative regulator of pathological cardiac hypertrophy by decreasing the TAK1 signaling to pro-hypertrophic members of the MAPK signaling pathway-Reference-Cited by-同舟云学术

FBXW5 acts as a negative regulator of pathological cardiac hypertrophy by decreasing the TAK1 signaling to pro-hypertrophic members of the MAPK signaling pathway

Published:2021-02 Issue: Volume:151 Page:31-43
ISSN:0022-2828
Container-title:Journal of Molecular and Cellular Cardiology
language:en
Short-container-title:Journal of Molecular and Cellular Cardiology

Author:

Hui Xuejun,Hu Fengjiao,Liu Jia,Li Changhai,Yang Yang,Shu Shangzhi,Liu Peipei,Wang Fan,Li Shuyan

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Molecular Biology

Reference48 articles.

1. Mechanisms of physiological and pathological cardiac hypertrophy;Nakamura;Nat. Rev. Cardiol.,2018

2. Cardiac hypertrophy: an introduction to molecular and cellular basis;Samak;Med. Sci. Monit. Basic Res.,2016

3. Physiological and pathological cardiac hypertrophy;Shimizu;J. Mol. Cell. Cardiol.,2016

4. The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling;Ji;Nat. Commun.,2016

5. Regulation of cardiac hypertrophy and remodeling through the dual-specificity MAPK phosphatases (DUSPs);Liu;J. Mol. Cell. Cardiol.,2016

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DPP2/7 is a Potential Predictor of Prognosis and Target in Immunotherapy in Colorectal Cancer: An Integrative Multi-omics Analysis;Combinatorial Chemistry & High Throughput Screening;2024-07

2. Dual-specificity phosphatase 26 protects against kidney injury caused by ischaemia-reperfusion through restraint of TAK1-JNK/p38-mediated apoptosis and inflammation of renal tubular epithelial cells;Toxicology and Applied Pharmacology;2024-06

3. FBXL8 inhibits post-myocardial infarction cardiac fibrosis by targeting Snail1 for ubiquitin-proteasome degradation;Cell Death & Disease;2024-04-13

4. Artemisinin Attenuates Isoproterenol-induced Cardiac Hypertrophy via the ERK1/2 and p38 MAPK Signaling Pathways;Current Molecular Pharmacology;2024-01-11

5. Pogostone alleviates angiotensin II-induced cardiomyocyte hypertrophy in H9c2 cells through MAPK and Nrf2 pathway;Tropical Journal of Pharmaceutical Research;2023-08-19